Efficacy of 90Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma

Hematological Oncology

Volumn 32, Issue 1, 2014, Pages 10-15

  Vanazzi, Anna ^a   Grana, Chiara ^a   Crosta, Cristiano ^a   Pruneri, Giancarlo ^a   Rizzo, Stefania ^a   Radice, Davide ^a   Pinto, Antonello ^b   Calabrese, Liliana ^a   Paganelli, Giovanni ^a   Martinelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Lymphoma; Radioimmunotherapy

Indexed keywords

CD20 ANTIGEN; IBRITUMOMAB TIUXETAN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB; YTTRIUM;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHEMOTHERAPY INDUCED ANEMIA; CHRONOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MALE; MARGINAL ZONE LYMPHOMA; MIDDLE AGED; NEUTROPENIA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; VERY ELDERLY; 90Y-IBRITUMOMAB TIUXETAN; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HEMATOLOGIC DISEASE; KAPLAN MEIER METHOD; LYMPHOMA; MULTIMODALITY CANCER THERAPY; PROSPECTIVE STUDY; RECURRENT DISEASE; SALVAGE THERAPY; STOMACH TUMOR; TREATMENT OUTCOME;

90Y-IBRITUMOMAB TIUXETAN; LYMPHOMA; RADIOIMMUNOTHERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOIMMUNOTHERAPY; RECURRENCE; SALVAGE THERAPY; STOMACH NEOPLASMS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84895522384     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2078     Document Type: Article

References (23)

1. Thieblemont C. Clinical presentation and management of marginal zone lymphomas. Hematology Am Soc Hematol Educ Program 2005; 1: 307-313.
2. Bertoni F, Zucca E. State-of-the-Art therapeutics: marginal-zone lymphoma. Clin Oncol 2005; 23(26): 6415-6420.
3. Pinotti G, Zucca E, Roggero E, et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma 1997; 26(5-6): 527-537.
4. Alpen B, Neubauer A, Dierlamm J, et al. Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection. Blood 2000; 95(12): 4014-4015.
5. Thieblemont C, Dumontet C, Bouafia F, et al. Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001. Leuk Lymphoma 2003; 44(2): 257-262.
6. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21(22): 4157-4164.
7. Gospodarowicz M, Tsang R. Radiation therapy of mucosa-associated lymphoid tissue (MALT) lymphomas. In MALT Lymphomas Bertoni F, Zucca E (eds). Landes Bioscience/Kluwer Academic: Georgetown, TX, 2004; 104-129.
8. Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000; 96(2): 410-419.
9. Conconi A, Cavalli F, Zucca E. MALT lymphomas: the role of chemotherapy. In MALT Lymphomas. Bertoni F, Zucca E (eds). Landes Bioscience/Kluwer Academic: Georgetown, TX, 2004; 99-103.
10. Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995; 13(10): 2524-2529.
11. Zinzani PL, Stefoni V, Musuraca G, et al. Fludarabine-containing chemotherapy as frontline treatment of non gastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 2004; 100(10): 2190-2194.
12. Jager G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 2002; 20(18): 3872-3877.
13. Wohrer S, Drach J, Hejna M, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol 2003; 14(12): 1758-1761.
14. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102(8): 2741-2745.
15. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23(9): 1979-1983.
16. Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol 2013; 31(5): 565-572.
17. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J Nucl Med 2003; 44(3): 465-474.
18. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20(10): 2453-2463.
19. Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007; 110(1): 54-58.
20. Esmaeli B, McLaughlin P, Pro B, et al. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 2009; 20(4): 709-714. doi:10.1093/annonc/mdn692.
21. Hoffmann M, Troch M, Eidherr H, et al. 90Y-Ibritumomab tiuxetan (zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma. Leuk Lymphoma 2011; 52(1): 42-45. doi:10.3109/10428194.2010.534519.
22. Cheson BD. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25(5): 579-586.
23. Copie-Bergman C, Gaulard P, Brousse N, et al. Proposal for a new histological grading system for post treatment evaluation of gastric MALT lymphoma. Gut 2003; 52(11): 1656.